SEC-HOPE: A multicenter retrospective cohort study to estimate secukinumab retention rate in psoriasis patients with MASLD.
Datos básicos
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
NOVARTIS FARMACEUTICA, S.A.
Cita
SEC-HOPE: A multicenter retrospective cohort study to estimate secukinumab retention rate in psoriasis patients with MASLD. (CAIN457AES18). NOVARTIS FARMACEUTICA, S.A. 2026IP:ANTONIO JAVIER SAHUQUILLO TORRALBA.
Portal de investigación